Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Awarded $12.9M Infectious Disease Biomarker Research Contract

NEW YORK (GenomeWeb News) – Montreal-based Caprion Proteomics has won a $12.9 million contract from the National Institute of Allergy and Infectious Diseases to research biomarkers for infectious diseases, the company said today.
 
Under the five-year contract, Caprion will act as one of two NIAID Clinical Proteomics Centers for Infectious Disease and Biodefense.
 
The company will use its CellCarta protein profiling technology to conduct large-scale applied proteomics projects on human clinical samples.
 
The studies Caprion will conduct will focus on discovering, qualifying, and verifying candidate biomarkers that can be used to detect, diagnose, and monitor responses to therapeutics and vaccines and disease susceptibility.
 
Caprion said this is its second biodefense contract from NIAID. The company is still working on a contract awarded in 2004 that is focused on identifying new immunotherapy targets, vaccines, and diagnostic candidates that are based on host and pathogen proteins that are involved in Brucella infections.
 
Under the agreement, Caprion will retain the rights to commercialize candidate biomarkers and diagnostic products it discovers under the project. Proteomics discoveries and validation results generated through the research will be made public through the Proteomics Research Program Administrative Center.
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.